Arbutus Biopharm

ABUS NASDAQ
1.460
-0.010
-0.68%
Closed 16:00 08/20 EDT
Open
1.500
Prev Close
1.470
High
1.500
Low
1.410
Volume
90.22K
Avg Vol (3M)
465.93K
52 Week High
11.25
52 Week Low
1.380
% Turnover
0.16%
Market Cap
83.00M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Arbutus Biopharm ABUS stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Arbutus Biopharma Corp is a Canada-based biopharmaceutical company. The Company is dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). The Company develops a portfolio of drug candidates with multiple mechanisms of action that results in a combination therapy to cure HBV. In addition to its HBV pipeline, the Company actively licenses its Lipid Nanoparticle (LNP) technology to its industry partners. This technology represents a delivery technology in RNA interference (RNAi) therapeutic development, which has enabled several clinical trials and has been administered to hundreds of human subjects.
MORE >

Recently

Name
Price
%Change